Tracked deals
5
5 tracked deals across 2021-2026.
Public Company
Healthcare
Merck & Co.
Rahway, New Jersey, United States
At Merck, unified around its purpose, we use the power of leading-edge science to save and improve lives through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company.
- Focus Areas
- Biopharmaceuticals, Medicines, Vaccines
- Website
- www.merck.com
Recent pace
1
1 tracked deal announced in the last 12 months.
Deal mix
Buyout
5 buyout
Merck & Co. Acquisition Volume by Year
Last 4 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
March 26, 2026
- Buyer
- Merck
- Target
- Terns Pharmaceuticals
- Industry
- Pharmaceuticals
- Location
- United States
- Type
- Buyout
Merck has agreed to acquire clinical-stage oncology company Terns Pharmaceuticals for approximately $6.7 billion (53.00 per share in cash). The deal is intended to add Terns’ lead asset TERN-701, an investigational oral allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia, to Merck’s hematology/oncology pipeline.
-
May 29, 2024
- Buyer
- Merck (Merck & Co., Inc.)
- Target
- EyeBio (Eyebiotech Limited)
- Industry
- Biotechnology
- Location
- England, United Kingdom
- Type
- Buyout
Merck (through a subsidiary) will acquire Eyebiotech Limited (EyeBio) for up to $3.0 billion — $1.3 billion upfront in cash plus up to $1.7 billion in development, regulatory and commercial milestones. The acquisition—expected to close in Q3 2024 and to be accounted for as an asset acquisition—adds EyeBio's ophthalmology-focused pipeline, including lead candidate Restoret (EYE103), to Merck's growing ophthalmology presence.
-
January 8, 2024
- Buyer
- Merck
- Target
- Harpoon Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
Merck has agreed to acquire clinical-stage immunotherapy company Harpoon Therapeutics for $23.00 per share in cash, representing an approximate total equity value of $680 million. The acquisition gives Merck access to Harpoon's TriTAC / ProTriTAC platforms and lead candidate HPN328 (a DLL3-targeting T‑cell engager) to enhance its oncology pipeline; the deal is expected to close in the first half of 2024, subject to customary conditions.
-
November 21, 2023
- Buyer
- Merck (MSD)
- Target
- Caraway Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Merck (MSD) will acquire Caraway Therapeutics, a Cambridge, Massachusetts–based preclinical biopharmaceutical company, for up to $610 million in potential consideration, including an undisclosed upfront payment and contingent milestone payments. The acquisition is intended to strengthen Merck’s research pipeline and capabilities in developing small-molecule treatments for genetically defined neurodegenerative and rare diseases.
-
February 25, 2021
- Buyer
- Merck
- Target
- Pandion Therapeutics
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
Merck will acquire Pandion Therapeutics for $60 per share in cash, representing an approximate total equity value of $1.85 billion, via a tender offer and subsequent merger. Pandion is a clinical-stage biotechnology company focused on precision immune modulators (TALON platform) with lead candidate PT101 targeting regulatory T cells for autoimmune diseases; the transaction is expected to close in the first half of 2021 subject to customary conditions.
Related Acquisition Pages
Selling a company? Get in front of buyers like Merck & Co.
Turn tracked acquisition activity into an outreach-ready buyer list.